Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients randomized ... Monthly Prescribing Reference: Zoryve Foam 0.3% Approved for Plaque Psoriasis of the Scalp, Body Tildrakizumab was well tolerated and achieved sustained response in patients with moderate to severe plaque psoriasis of the scalp in a phase 3 study.

Understanding the Context

This study excluded patients with predominantly ... Many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin. But some people with moderate or severe plaque psoriasis have symptoms that do ... Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Key Insights

Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ... Essence: Health Matters: New Data Reveals What You Need To Know About Scalp Psoriasis Health Matters: New Data Reveals What You Need To Know About Scalp Psoriasis